William Cliby, MD, consultant, division of gynecologic surgery, department of obstetrics & gynecology, Mayo Clinic, discusses patient factors that predispose them to adverse complications during surgery for ovarian cancer and using those predictors to improve care.
William Cliby, MD, consultant, division of gynecologic surgery, department of obstetrics & gynecology, Mayo Clinic, discusses patient factors that predispose them to adverse complications during surgery for ovarian cancer and using those predictors to improve care.
Transcript
What patient factors would predispose them to adverse complications during surgery for ovarian cancer?
That’s very important. A big part of what we’ve been doing the last 10 or 15 years is identifying the risk factors for serious complications after ovarian cancer surgery. Of course, the importance of surgery in leaving very little residual disease on survival is known and accepted. But, sometimes doing those surgeries are quite complex, and patients can have bad complications as a result. So, we’ve identified that the factors that most predict complications are, again, the patient’s age, performance status, or some measure of their frailty, and then their nutrition level.
Patients that have any of those factors at are negative, they really have a high and probably unacceptably high risk from upfront surgery. So, they’re better served by some other way to address their ovarian cancer, perhaps adding in surgery later in the course of their treatment.
How can you use these predictors to improve quality of care and management of ovarian cancer?
So, for us, it’s about not taking a one size fits all approach. We shouldn’t treat most patients with chemotherapy first and then surgery, and we shouldn’t try to treat all patients with surgery first and then chemotherapy. Using these factors that I mentioned before, patient factors, as well as the treating centers factors, we can triage patients best to what they can tolerate to get them best overall care.
We’re not so focused on just the surgical outcomes. We’ve got a long battle to wage against ovarian cancer that we want to have the best overall outcome.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More